首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF13B |
| Uniprot No | Q9Y275 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 134-285aa |
| 氨基酸序列 | AVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL |
| 预测分子量 | 46.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF13B(BAFF)重组蛋白的参考文献示例(文献名称与作者为虚构示例，供参考格式)：
1. **文献名称**: *Structural and functional characterization of recombinant TNFSF13B in B-cell activation*
**作者**: Smith J, et al.
**摘要**: 研究通过哺乳动物表达系统纯化的重组TNFSF13B蛋白的三维结构及其与BAFF受体的结合特性，揭示其促进B细胞增殖的关键结构域。
2. **文献名称**: *Recombinant TNFSF13B enhances survival of malignant B cells in vitro*
**作者**: Lee H, et al.
**摘要**: 证明重组TNFSF13B蛋白通过激活NF-κB通路抑制B细胞肿瘤凋亡，提示其在肿瘤微环境中的潜在病理作用。
3. **文献名称**: *Optimization of TNFSF13B expression in CHO cells for therapeutic applications*
**作者**: Chen R, et al.
**摘要**: 开发中国仓鼠卵巢(CHO)细胞高效表达重组TNFSF13B的工艺，验证其稳定性与生物活性，为规模化生产提供基础。
4. **文献名称**: *TNFSF13B transgenic mice develop systemic autoimmune phenotypes*
**作者**: Wang Y, et al.
**摘要**: 通过过表达重组TNFSF13B构建小鼠模型，证实其导致B细胞过度活化和狼疮样症状，支持BAFF在自身免疫疾病中的关键作用。
**注意**：以上文献为示例性质，实际引用时建议通过PubMed或学术数据库检索真实文献。
TNFSF13B, also known as B-cell activating factor (BAFF) or BLyS (B lymphocyte stimulator), is a member of the tumor necrosis factor (TNF) superfamily. This cytokine plays a critical role in B cell development, survival, and differentiation by binding to three receptors: BAFF-R (BR3), TACI, and BCMA. It is primarily produced by innate immune cells, including macrophages, dendritic cells, and neutrophils, and is essential for maintaining humoral immunity and secondary lymphoid organ structure.
Recombinant TNFSF13B protein is generated through genetic engineering, typically using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications, such as glycosylation, which are vital for its biological activity. The purified protein usually exists as a homotrimer, mimicking the native structure required for receptor engagement. Its production enables researchers to study BAFF/BAFF-R signaling pathways, autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis), and B cell-related malignancies.
In therapeutic contexts, excessive BAFF signaling is linked to autoimmune disorders, leading to the development of BAFF inhibitors like belimumab. Conversely, recombinant TNFSF13B may serve as an immune adjuvant or a potential treatment for immunodeficiencies. Quality assessments, including SDS-PAGE, Western blot, and functional assays (e.g., B cell proliferation tests), are performed to confirm its bioactivity and purity. Its applications span in vitro studies, animal disease models, and drug discovery, offering insights into immune regulation and targeted therapy strategies.
×
